Healthcare Technology Startup IsoPlexis Brings In $13.5 Million

IsoPlexis completed $13.5 million in Series B financing. Spring Mountain Capital led the round,  with participation from Connecticut Innovations, Ironwood Capital, and North Sound Ventures.

IsoPlexis is a life sciences company that is developing a cellular response analysis platform that identifies a wide range of patient immune responses at the single-cell level. Its platform assesses the safety and efficacy of therapeutics and monitors disease progression, informing physician decisions and enabling improved therapeutic development.

According to the company, the new funding will help IsoPlexis accelerate its current momentum.